A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects
Trial Summary
What is the purpose of this trial?
This trial will test a new drug called LEO 138559 in healthy Japanese people. It will check how the drug moves through their bodies, if it causes any immune reactions, and if it is safe to use.
Will I have to stop taking my current medications?
The trial requires participants to stop taking certain medications, including immunosuppressive or immunomodulating drugs, topical corticosteroids, topical calcineurin inhibitors, and over-the-counter medications or herbal remedies, before joining. Paracetamol/acetaminophen is allowed up to 2 g per day.
Research Team
Medical Expert
Principal Investigator
LEO Pharma
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Single treatment with either LEO 138559 or placebo administered subcutaneously up to 3 injections per dosing
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- LEO 138559
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
LEO Pharma
Lead Sponsor
Christophe Bourdon
LEO Pharma
Chief Executive Officer since 2022
Engineering degree from Université de Technologie de Compiègne
Dr. Siri Torhaug
LEO Pharma
Chief Medical Officer since 2022
MD, PhD